Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) has earned an average recommendation of “Buy” from the twenty-three brokerages that are currently covering the company, Analyst Ratings News reports. Six research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $344.00.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, June 25th. They now have a $334.00 price target on the stock. Separately, analysts at Goldman Sachs reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, June 24th.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 280.27 on Monday. Regeneron Pharmaceuticals has a one year low of $225.78 and a one year high of $352.49. The stock’s 50-day moving average is $298.0 and its 200-day moving average is $299.1. The company has a market cap of $27.665 billion and a price-to-earnings ratio of 79.50.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 8th. The company reported $0.58 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.94 by $0.36. The company had revenue of $626.00 million for the quarter, compared to the consensus estimate of $609.04 million. During the same quarter last year, the company posted $1.78 earnings per share. Regeneron Pharmaceuticals’s revenue was up 42.3% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post $9.90 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.